Achieve Life Sciences (STU:SP4P) Short Percentage of Float

View and export this data going back to 2014. Start your Free Trial

What is Achieve Life Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Achieve Life Sciences's Short Percentage of Float

For the Biotechnology subindustry, Achieve Life Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Short Percentage of Float falls into.

Achieve Life Sciences (STU:SP4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (STU:SP4P) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

ACHV:USA SP4P:Germany

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences (STU:SP4P) Headlines

No Headlines